Patents by Inventor Josephine M. Cardarelli

Josephine M. Cardarelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11220548
    Abstract: The present disclosure provides a method for treating a subject afflicted with Waldenström's macroglobulinemia (WM) comprising administering to the subject a therapeutically effective amount of an antibody or an antigen-binding portion thereof that specifically binds to a CXCR4 receptor expressed on the surface of a WM cell. The disclosure also provides a therapeutic regimen for treating a patient afflicted with C1013G/CXCR4-associated WM.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: January 11, 2022
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, DANA-FARBER CANCER INSTITUTE, Inc.
    Inventors: Irene M. Ghobrial, Aldo M. Roccaro, Josephine M. Cardarelli, Antonio Sacco
  • Publication number: 20210395375
    Abstract: The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.
    Type: Application
    Filed: June 22, 2021
    Publication date: December 23, 2021
    Inventors: Josephine M. CARDARELLI, Alison WITTE, Mohan SRINIVASAN
  • Publication number: 20210363267
    Abstract: This disclosure provides combination therapy for treating a subject, such as a subject afflicted with a lung cancer, comprising administering to the subject an anti-fucosyl-GM1 antibody and an anti-CD137 antibody, or antigen-binding portions of either or both.
    Type: Application
    Filed: July 28, 2021
    Publication date: November 25, 2021
    Inventors: Josephine M. CARDARELLI, Daniel E. LOPES de MENEZES, Paul D. PONATH, Bingliang CHEN, Chin PAN
  • Patent number: 11104739
    Abstract: This disclosure provides combination therapy for treating a subject, such as a subject afflicted with a lung cancer, comprising administering to the subject an anti-fucosyl-GM1 antibody and an anti-CD137 antibody, or antigen-binding portions of either or both.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: August 31, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Josephine M. Cardarelli, Daniel E. Lopes de Menezes, Paul D. Ponath, Bingliang Chen, Chin Pan
  • Patent number: 11072664
    Abstract: The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: July 27, 2021
    Assignee: E.R. Squibb & Sons, L.L.C.
    Inventors: Josephine M. Cardarelli, Alison Witte, Mohan Srinivasan
  • Publication number: 20200231683
    Abstract: The present disclosure provides human monoclonal antibodies that bind specifically to CXCR4 with high affinity. This disclosure also provides a method for treating a subject afflicted with a CXCR4-expressing cancer, in particular a hematological malignancy such as multiple myeloma, acute myeloid leukemia, or non-Hodgkin's lymphoma, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an anti-CXCR4 antibody of the disclosure. The disclosure further provides a kit for treating a cancer in a subject comprising a dose of an anti-CXCR4 antibody and instructions for using the anti-CXCR4 antibody in the therapeutic methods of the disclosure.
    Type: Application
    Filed: October 1, 2019
    Publication date: July 23, 2020
    Inventors: MICHELLE R. KUHNE, Chin Pan, Josephine M. Cardarelli
  • Publication number: 20200138945
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
    Type: Application
    Filed: October 11, 2019
    Publication date: May 7, 2020
    Applicants: E.R. SQUIBB & SONS, L.L.C., Ono Pharmaceutical Co., LTD.
    Inventors: Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, Haichun Huang
  • Publication number: 20200031945
    Abstract: The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.
    Type: Application
    Filed: July 3, 2019
    Publication date: January 30, 2020
    Inventors: Josephine M. CARDARELLI, Alison WITTE, Mohan SRINIVASAN
  • Publication number: 20200002428
    Abstract: The present disclosure provides a method for treating a subject afflicted with Waldenström's macroglobulinemia (WM) comprising administering to the subject a therapeutically effective amount of an antibody or an antigen-binding portion thereof that specifically binds to a CXCR4 receptor expressed on the surface of a WM cell. The disclosure also provides a therapeutic regimen for treating a patient afflicted with C1013G/CXCR4-associated WM.
    Type: Application
    Filed: February 8, 2019
    Publication date: January 2, 2020
    Inventors: Irene M. Ghobrial, Aldo M. Roccaro, Josephine M. Cardarelli, Antonio Sacco
  • Publication number: 20190315881
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting Fucosyl-GM1, as well as methods for treating various diseases, including cancer, using anti-Fucosyl-GM1 antibodies.
    Type: Application
    Filed: May 17, 2019
    Publication date: October 17, 2019
    Inventors: Cynthia A. VISTICA, Eric H. Holmes, Peter Brams, Alison Witte, Josephine M. Cardarelli
  • Patent number: 10441655
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: October 15, 2019
    Assignees: ONO PHARMACEUTICAL CO., LTD., E.R. SQUIBB & SONS, L.L.C.
    Inventors: Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, Haichun Huang
  • Patent number: 10428151
    Abstract: The present disclosure provides human monoclonal antibodies that bind specifically to CXCR4 with high affinity. This disclosure also provides a method for treating a subject afflicted with a CXCR4-expressing cancer, in particular a hematological malignancy such as multiple myeloma, acute myeloid leukemia, or non-Hodgkin's lymphoma, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an anti-CXCR4 antibody of the disclosure. The disclosure further provides a kit for treating a cancer in a subject comprising a dose of an anti-CXCR4 antibody and instructions for using the anti-CXCR4 antibody in the therapeutic methods of the disclosure.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: October 1, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michelle R. Kuhne, Chin Pan, Josephine M. Cardarelli
  • Patent number: 10385133
    Abstract: The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: August 20, 2019
    Assignee: E.R. Squibb & Sons, L.L.C.
    Inventors: Josephine M. Cardarelli, Alison Witte, Mohan Srinivasan
  • Patent number: 10358490
    Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: July 23, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Brenda L. Stevens, Alison Witte, Mark W. Rixon, Josephine M. Cardarelli, Thomas D. Kempe, Scott R. Presnell, Mohan Srinivasan, Susan C. Wong, Guodong Chen, Hui Wei, Stanley R. Krystek, Lumelle A. Schneeweis, Paul O. Sheppard, Indrani Chakraborty
  • Publication number: 20190218294
    Abstract: A method of treating a tumor in a patient by administering to the patient a therapeutically effective amount of a combination of an anti-PD-1 antibody and an anti-mesothelin antibody-drug conjugate.
    Type: Application
    Filed: September 7, 2017
    Publication date: July 18, 2019
    Inventors: Shivani SRIVASTAVA, Deanne LATHERS, Heather E. VEZINA, Josephine M. CARDARELLI, Peter SABBATINI, Mark S. WADE, Chin PAN
  • Publication number: 20190119395
    Abstract: This disclosure provides combination therapy for treating a subject, such as a subject afflicted with a lung cancer, comprising administering to the subject an anti-fucosyl-GM1 antibody and an anti-CD137 antibody, or antigen-binding portions of either or both.
    Type: Application
    Filed: April 14, 2017
    Publication date: April 25, 2019
    Inventors: Josephine M. CARDARELLI, Daniel E. LOPES de MENEZES, Paul D. PONATH, Bingliang CHEN, Chin PAN
  • Patent number: 10233248
    Abstract: The present disclosure provides a method for treating a subject afflicted with Waldenstrm's macroglobulinemia (WM) comprising administering to the subject a therapeutically effective amount of an antibody or an antigen-binding portion thereof that specifically binds to a CXCR4 receptor expressed on the surface of a WM cell. The disclosure also provides a therapeutic regimen for treating a patient afflicted with C1013G/CXCR4-associated WM.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: March 19, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Irene M. Ghobrial, Aldo M. Roccaro, Josephine M. Cardarelli, Antonio Sacco
  • Publication number: 20190031763
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CXCR4 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CXCR4, as well as methods for treating various cancers, inflammatory disorders and HIV infection using an anti-CXCR4 antibody of this disclosure.
    Type: Application
    Filed: October 12, 2018
    Publication date: January 31, 2019
    Inventors: MICHELLE R. KUHNE, Peter Brams, Dawn M. Tanamachi, Alan J. Korman, Josephine M. Cardarelli
  • Patent number: 10106615
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CXCR4 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CXCR4, as well as methods for treating various cancers, inflammatory disorders and HIV infection using an anti-CXCR4 antibody of this disclosure.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: October 23, 2018
    Assignee: E. R. SQUIBB & SONS, L.L.C.
    Inventors: Michelle Kuhne, Peter Brams, Dawn M. Tanamachi, Alan Korman, Josephine M. Cardarelli
  • Publication number: 20180179282
    Abstract: This disclosure provides a method for treating a subject afflicted with a cancer comprising administering to the subject a combination of therapeutically effective amounts of an antibody or an antigen-binding portion thereof that binds specifically to Programmed Death-1 (PD-1) or to Programmed Death Ligand-1 (PD-L1), and an antibody or an antigen-binding portion thereof that binds specifically to C-X-C Chemokine Receptor 4 (CXCR4) or to C-X-C motif chemokine 12 (CXCL12). The disclosure also provides a kit for treating a subject afflicted with a cancer, the kit comprising one or more dosages of an antibody or an antigen-binding portion thereof that binds specifically to PD-1 or to PD-L1, one or more dosages of an antibody or an antigen-binding portion thereof that binds specifically to CXCR4 or to CXCL12, and instructions for using the antibodies or portions thereof for treating the subject.
    Type: Application
    Filed: June 13, 2016
    Publication date: June 28, 2018
    Inventors: Josephine M. Cardarelli, Wendy L. Clemens, Glenn S. Kroog, Daniel E. Lopes de Menezes, Chin Pan, Paul D. Ponath, Jean Viallet